Agilent, CambTEK Announce LC Sample Prep Agreement
News Feb 26, 2014
Used together, these laboratory solutions provide analytical researchers in the pharmaceutical, chemical and food industries with powerful tools to increase the speed and efficiency of laboratory workflows and maximize the quality of their results.
"Continuing advancements in analytical technology are enabling faster, more robust analysis capabilities in the laboratory, but work is getting trapped in the bottleneck of the sample preparation workflow," said Christian Gotenfels, Agilent's senior product manager for liquid chromatography. "By offering a combined solution for liquid chromatography sample preparation, our complementary technologies will enable analytical researchers to access faster and more robust workflow solutions to achieve higher productivity and data quality."
CambTEK's Rapid Extraction System (RES) is a sample preparation instrument designed for rapid extraction of solid dose forms and gels, with important applications in the pharmaceutical, chemical and food science industries. The RES provides enhanced data quality with increased speed and productivity. It is highly versatile and capable of processing a wide range of sample types, including tablets, powders, capsules, gels/pastes, beads, swabs and stents.
"We are delighted to partner with Agilent to co-market our solutions for the preparation and analysis of solid dosage forms," said CambTEK Chief Executive Officer Dr. Hugh Malkin. "Used together, these technologies will deliver significant benefits to our customers."
Rapid Removal of Arsenic From Drinking Water...By Moss!News
A moss capable of removing arsenic from contaminated water has been discovered by researchers. And it happens quickly – in just one hour, the arsenic level is so low that the water is no longer harmful for people to drink.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.